Healthcare
Live Price
Offline$3.70
+2.21% today
1Y Change
+188.46%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zentalis Pharmaceuticals, Inc. (ZNTL) is a Healthcare stock with a market cap of $280.00M and listed on NASDAQ. The stock last traded around $3.70 and up 188.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +18.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +18.0%, free cash flow +26.8% with operating margin 0.0% and ROIC -59.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZNTL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZNTL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZNTL Max Drawdown
-46.75%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZNTL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$158.7M
+33.0% YoY
Free Cash Flow
-$160.2M
+3.7% YoY
Revenue Growth
-100.0%
EPS Growth
+18.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 67M | 0 | 0 | 0 |
| Gross Profit | -739K | 67M | 0 | 0 | 0 |
| Operating Income | -146M | -191M | -300M | -227M | -217M |
| EBITDA | -146M | -186M | -248M | -226M | -207M |
| Net Income | -137M | -166M | -292M | -237M | -159M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36M | 34M | 28M | 43M | 60M |
| Total Assets | 289M | 430M | 562M | 553M | 472M |
| Total Liabilities | 73M | 93M | 125M | 119M | 108M |
| Shareholder Equity | 216M | 337M | 437M | 434M | 364M |
| Total Debt | 40M | 43M | 46M | 47M | 46M |
| Net Debt | 4M | 9M | 18M | 4M | -14M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
154M
+5.9% YoY
Capital Expenditures
6M
-139.7% YoY
Free Cash Flow
160M
+3.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-52.8%
Debt / Equity
0.18x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.